Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

P

Utilizziamo cookie essenziali, di analisi e pubblicitari per migliorare l'esperienza, misurare l'utilizzo e ottimizzare le campagne.

Essenziali

Necessari per il funzionamento del sito e non disattivabili.

Analitici

Ci aiutano a comprendere l'utilizzo per migliorare il servizio.

Pubblicitari

Ci permettono di misurare le campagne e ottimizzare la pubblicità relativa ai nostri servizi.

Maggiori informazioni su Informativa sulla privacy · Termini di Servizio · Cookie Policy

Description

Europe

Health & Life Sciences•100% • 37.3M€

Pending

Dates & Deadlines

Publication Date

October 16, 2026

Opening Date

October 29, 2026

Application Phases

Fase única

February 17, 2027 at 05:00 PM

Financial Details

Non-Refundable

Maximum Funding Rate

100%

Budget

37.3M€

Eligible Project Value

Up to 10M€

Criteria & Documents

Eligible Expenses

●Personnel Costs
●Travel costs
●Equipment costs
●Other goods, works and services costs
●Subcontracting
●Indirect Costs

Access Conditions

●Legal entities from EU Member States and Associated Countries
●Consortium must include partners from at least three different EU Member States or Associated Countries
●Compliance with general and specific admissibility and eligibility criteria

Selection Criteria

●Excellence (scientific and technical merit)
●Impact (contribution to policy and partnership KPIs)
●Quality and efficiency of implementation

Mandatory Information

●Application form (Part A and Part B)
●Budget

Result Indicators

●Reduction of disease burden (DALYs)
●Decrease in premature mortality from non-communicable diseases
●Increased health system preparedness
●Number of new or improved therapies developed

EU Programme Details

Call ID: HORIZON-HLTH-2027-01-DISEASE-06
Cluster: Health
Destination: D3. Tackling diseases and reducing disease burden
Submission Mode: Single-stage
EU Contribution: Around €9,000,000.00 to €10,000,000.00 per project
Expected Projects: 4 projects
Funding Rate Rule: Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Funding Rate

100%

Budget

37.3M€

Curated by

Marlene Faria

Eligibility

Eligible Sectors

Health & Life Sciences

Company Typologies

MicroSMESmall Mid-CapMid-CapLargeNon-business entities of the R&I system (ENESII)Private non-profit entitiesPublic entities

Application Mode

Consortium / Copromotion

Action Types

Research and Innovation ActionCollaborative Project

Official Links

Official Regulation